Table 2.
Improvements from baseline to 6-month follow-up in symptoms and quality of life by treatment group (iterative matching sample).
| TAM | HESr | p value | |||
|---|---|---|---|---|---|
| n | Mean (SD) | n | Mean (SD) | ||
| IPSS total | 335 | 5.0 (4.3) | 369 | 4.5 (4.7) | 0.117 |
| IPSS voiding sub-score | 335 | 2.9 (2.8) | 369 | 2.5 (3.1) | 0.051 |
| IPSS storage sub-score | 335 | 2.1 (2.1) | 369 | 2.0 (2.3) | 0.527 |
| Nocturia | 335 | 0.6 (0.9) | 369 | 0.6 (1.0) | 0.539 |
| BII total | 335 | 2.3 (2.4) | 369 | 2.2 (2.5) | 0.417 |
| IPSS 8 (QoL) | 335 | 1.3 (1.2) | 369 | 1.1 (1.2) | 0.129 |
TAM: tamsulosin; HESr: hexanic extract of Serenoa repens; IPSS: International Prostate Symptom Score; BII: Benign Prostatic Hyperplasia Impact Index; QoL: quality of life.